Understand the source comparison
How to Lose 20 Pounds With Peptides: Comparison
The table below compares the two primary GLP-1 receptor agonists used in weight reduction protocols, their titration schedules, clinical trial outcomes, and practical implementation differences. Semaglutide GLP-1 receptor agonist. Slows gastric emptying, suppr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares the two primary GLP-1 receptor agonists used in weight reduction protocols, their titration schedules, clinical trial outcomes, and practical implementation differences.
- Semaglutide
- GLP-1 receptor agonist. Slows gastric emptying, suppresses appetite via hypothalamic signaling
- 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg weekly (16–20 week escalation)
- 14.9% body weight at 68 weeks (STEP-1 trial, 2.4mg dose)
- ~5 days
- Gold-standard for weight reduction research. Most data, longest track record, well-tolerated at slow titration
- Tirzepatide
- Dual GLP-1/GIP agonist. Broader receptor activity, slightly greater appetite suppression
- 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg weekly (20–24 week escalation)
- 20.9% body weight at 72 weeks (SURMOUNT-1 trial, 15mg dose)
- Stronger appetite suppression in head-to-head comparisons, but higher GI side effect rates during titration. Best for subjects who plateau on semaglutide
- Liraglutide
- GLP-1 receptor agonist (daily injection)
- 0.6mg daily → 1.2mg → 1.8mg → 3.0mg (4–5 week escalation)
- 8.0% body weight at 56 weeks (SCALE trial, 3.0mg dose)
- ~13 hours
- Older compound with weaker outcomes than weekly agonists. Daily injection burden limits compliance in long-term protocols